KORU Medical Systems, Inc. (NASDAQ: KRMD), a prominent medical technology company specializing in innovative large-volume subcutaneous infusion solutions, recently shared data highlighting nursing preference for the KORU FreedomEdge® Infusion System for administering subcutaneous oncology infusions in clinical settings. These findings were presented at the PODD 2024 Conference on October 28, 2024, in Boston, Massachusetts.
The Nursing Preference Study aimed to evaluate the time spent with patients, the impact on nursing and patient comfort, and overall nurse preference when comparing manual syringe administration to the KORU FreedomEdge® Infusion System for subcutaneous oncology biologic drug infusions. Conducted by KORU Medical across six hospitals in Denmark, the study involved 33 nurses administering over 3,000 infusions of an oncology drug greater than 10 mL, with an average administration time of about 10 minutes.
Key findings included:
- Increased Patient Interaction: 97% of nurses reported having more time to engage with patients when using the KORU FreedomEdge® Infusion System compared to manual syringe administration.
- Reduced Nurse Discomfort: 81% of nurses experienced less hand pain using the KORU system.
- Ease of Use: 91% found the KORU system easier to operate, with a shorter setup time.
- Reduced Patient Discomfort: 73% observed less patient pain during infusions with the KORU system.
- Strong Recommendations: 97% of nurses would recommend the KORU FreedomEdge® Infusion System, citing ease of use and reduced discomfort as key benefits.
As the trend toward subcutaneous formulations of previously intravenous biologics grows among oncology pharmaceutical manufacturers, the study underscores the potential for efficient drug delivery solutions. An estimated one million global infusions of greater-than-5mL biologic oncology drugs have been approved for in-clinic administration.
Linda Tharby, President and CEO of KORU Medical, noted, “The increasing prevalence of large-volume subcutaneous oncology therapies poses challenges for manual administration, particularly concerning workflow disruptions due to lengthy administration times.”
She added, “KORU’s FreedomEdge® Infusion System provides a viable alternative that simplifies the drug delivery process. We are excited to see the positive feedback from this study and plan to file for FDA clearance for our system with an oncology biologic in 2025.”
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes innovative, patient-centric large-volume subcutaneous infusion solutions that enhance the quality of life for patients worldwide. The FREEDOM Syringe Infusion System includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. Since its first FDA clearance in 1994, the Freedom System has been used for both self-administration at home and professional administration in ambulatory infusion centers. Through its Novel Therapies division, KORU Medical also supports biopharmaceutical companies in clinical trials and can customize the Freedom System for various drug categories.
